Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies.
Wei Y, Erfani S, Schweer D, de Gouvea R, Qadir J, Shi J, Cheng K, Wu D, Craven R, Wu Y, Olivier T, Baldwin LA, Zhou B, Zhou Y, Zhao W, Yang BB, Ueland FR, Yang XH.
Wei Y, et al. Among authors: qadir j.
Mol Ther Oncolytics. 2023 Feb 19;28:293-306. doi: 10.1016/j.omto.2023.02.006. eCollection 2023 Mar 16.
Mol Ther Oncolytics. 2023.
PMID: 36911068
Free PMC article.
Review.